US drug tariffs may not hit branded prices hard, but generics and supply chains face disruption. Here’s what pharma leaders need to know.

FluidForm Bio’s 3D bioprinting tech keeps lab-grown cells alive five times deeper using vascular-like gelatin scaffolds.

The UK government has formally signed into law new clinical trial regulations, designed to modernise operations across the country.

CloudSpec speeds up lipid nanoparticle analysis, cutting lab times from hours to seconds for gene therapy and vaccine research.

The UK government has announced a significant new initiative to accelerate drug discovery and improve patient care in the country.  

Pharma must balance creativity with transparency to rebuild trust in 2025. VML Health’s report reveals key trends shaping expectations.

Novo Nordisk has announced major leadership changes, with EVP Camilla Sylvest departing and Ludovic Helfgott taking on an expanded role.

From the latest news impacting the UK’s NHS to large industry acquisitions, March brought a range of impactful news.

Discover the latest pharma innovations, from needle-free vaccines to NHS data access and interactive case studies in medical education.

A gene therapy for heart failure with preserved ejection fraction (HFpEF) has shown promising early results.

This decision underscores the need for a preventative measure against the chlamydia, which affects millions worldwide.

A new study is challenging the belief that dementia is incompatible with modern work environments, with AI helping employees stay in work.

The biopharmaceutical industry’s return on investment in innovation is increasing, but R&D costs are rising, according to a new Deloitte report.

The industry already contributes more than £17.6 billion directly to the UK economy, but it believes that growth has stagnated because of VPAG.

Pfizer has announced plans to sell its remaining stake in Haleon plc, divesting approximately 662 million shares.

AstraZeneca has announced a $1bn agreement to acquire EsoBiotec, a Belgian biotech firm pioneering in vivo cell therapies.

The NICE has approved the first daily oral treatment for endometriosis symptoms for use within the NHS in England.

A DMT-based treatment for people with treatment-resistant depression (TRD) has entered Phase 2 clinical trials.

The UK MHRA has validated Bavarian Nordics’ marketing authorisation application for its single-dose chikungunya vaccine.

In a deal worth approximately $935m, Jazz Pharmaceuticals is set to acquire Chimerix, a biotechnology company developing oncology therapies.

From a historic vaccine approval to a $50bn investment reshaping US drug manufacturing, February brought major pharma news to the fore.

The UK must increase investment in innovative medicines and vaccines if it is to deliver on the NHS 10-Year Plan and drive economic growth.

The Trump administration is set to cut a total of $60bn in US assistance worldwide, signalling a major shift in health policy.

The company’s investment will expand its US manufacturing footprint and is the largest investment of its kind in history.

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV prevention.

FibroGen, Inc. has announced the sale of its Chinese subsidiary to AstraZeneca, including the rights to roxadustat in China.

The FDA has granted priority review to zongertinib for non-small cell lung cancer (NSCLC).

A new cross-industry report is calling for the UK’s NHS to design its health data infrastructure to meet the needs of pharma researchers.

A new at-home genetic test that assesses the risk of developing coeliac disease has received approval from US regulators.

Robert F. Kennedy Jr has been confirmed as the US Secretary of Health and Human Services following a 52-48 Senate vote.

A new survey from the ABPI has revealed a surge in apprenticeships, placements and global research collaborations in the UK pharma space.

To boost its cardiovascular pipeline, Novartis has announced the acquisition of the company it co-founded with Blackstone Life Sciences.

Obinutuzumab could reshape the treatment of lupus nephritis, a life-threatening complication of lupus that has long lacked effective options.

Two companies have come together to enhance the way imaging technology is used to assess treatment responses in progressive pulmonary fibrosis.

The world’s first chikungunya vaccine, developed by French pharmaceutical firm Valneva SE, has been approved in the UK by the MHRA.

Marco Rubio has authorised an “Emergency Humanitarian Waiver” that ensures continued access to HIV treatment funded by the US.

The World Health Organization has responded to the US government’s freezing of HIV funding as part of a broader pause in foreign aid.

Catch up on January’s top pharma news, from major industry deals and cutting-edge medical innovations to advancements in women’s health.

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.

According to new findings by the HBA and FemTechnology, there are significant systemic challenges and unmet needs in women’s healthcare

Takeda is serving as the Industry Lead in the newly launched INTERCEPT project – a multinational collaboration to identify predictive biomarkers for Crohn’s Disease.

The Healthcare Businesswomen’s Association (HBA) has announced its 2025 winners as Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US.

The company’s microbot technology holds huge potential for exploring and delivering treatments to the brain.

The European pharma sector is on the brink of regulatory and operational updates with new papers from pharmaceutical associations 

New analysis from GlobalData spans the growth of the heart failure market across seven major markets including the US, Europe and Japan. 

Micron Biomedical, an Atlanta-based life sciences company, has received funding for its technology that could improve vaccine access.

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and beta-thalassemia.

WuXi Biologics sells its vaccine production facility in Ireland to Merck & Co for $500m in the wake of changing regulation in the US.

According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.

Novartis’ Phase III study has demonstrated significant improvement in motor function in children and young adults with spinal muscular atrophy

Discover the latest examples of how pharma and its partners are working together to develop technology to solve key industry challenges.

Catch up on all the latest pharmaceutical industry news from the past month, from breakthroughs in gene therapy to promising drug approvals and more.

Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep disorder.

Tessera Therapeutics has announced a partnership with the Bill & Melinda Gates Foundation, securing funding of up to $50m.

A new report by the Office of Health Economics (OHE), commissioned by Pfizer, reveals that respiratory infections can be bad for business.

The drug has received a nod from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).